First-in-human randomised trial and follow-up study of Plasmodium falciparum blood-stage malaria vaccine BK-SE36 with CpG-ODN(K3)-Reference-Cited by-同舟云学术

First-in-human randomised trial and follow-up study of Plasmodium falciparum blood-stage malaria vaccine BK-SE36 with CpG-ODN(K3)

Published:2020-10 Issue:46 Volume:38 Page:7246-7257
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Ezoe Sachiko,Palacpac Nirianne Marie Q.,Tetsutani Kohhei,Yamamoto Kouji,Okada Kiyoshi,Taira Masaki,Nishida Sumiyuki,Hirata Haruhiko,Ogata Atsushi,Yamada Tomomi,Yagi Masanori,Edula Jyotheeswara R.,Oishi Yuko,Tougan Takahiro,Ishii Ken J.,Myoui Akira,Horii Toshihiro

Funder

Japan Agency for Medical Research and Development

Ministry of Education, Culture, Sports, Science and Technology

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference43 articles.

1. World Malaria Report 2019;WHO,2019

2. Malaria vaccines: recent advances and new horizons;Draper;Cell Host Microbe,2018

3. Prospects for malaria vaccines: pre-erythrocytic stages, blood stages, and transmission-blocking stages;Zheng;Biomed Res Int,2019

4. RTS,S malaria vaccine pilots in three African countries;Adepoju;Lancet,2019

5. Plasmodium falciparum blood stage antimalarial vaccines: an analysis of ongoing clinical trials and new perspectives related to synthetic vaccines;Salamanca;Front Microbiol,2019

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Malaria transmission blocking activity of Anopheles stephensi alanyl aminopeptidase N antigen formulated with MPL, CpG, and QS21 adjuvants;PLOS ONE;2024-07-05

2. Camptothecin-loaded mesoporous silica nanoparticles functionalized with CpG oligodeoxynucleotide as a new approach for skin cancer treatment;International Journal of Pharmaceutics;2024-07

3. Vaccines and monoclonal antibodies: new tools for malaria control;Clinical Microbiology Reviews;2024-06-13

4. Immune tolerance caused by repeated P. falciparum infection against SE36 malaria vaccine candidate antigen and the resulting limited polymorphism;Parasitology International;2024-04

5. Persistence of Anti-SE36 Antibodies Induced by the Malaria Vaccine Candidate BK-SE36/CpG in 5–10-Year-Old Burkinabe Children Naturally Exposed to Malaria;Vaccines;2024-02-06